Talbot Financial LLC Increases Stake in Pfizer Inc. $PFE

Talbot Financial LLC raised its position in Pfizer Inc. (NYSE:PFE) by 29.9% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 428,087 shares of the biopharmaceutical company’s stock after purchasing an additional 98,613 shares during the period. Talbot Financial LLC’s holdings in Pfizer were worth $10,377,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the period. Vest Financial LLC raised its holdings in shares of Pfizer by 73.5% during the 1st quarter. Vest Financial LLC now owns 47,252 shares of the biopharmaceutical company’s stock worth $1,197,000 after acquiring an additional 20,018 shares during the period. Signal Advisors Wealth LLC raised its holdings in shares of Pfizer by 16.6% during the 1st quarter. Signal Advisors Wealth LLC now owns 8,826 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 1,258 shares during the period. Finally, Insight Advisors LLC PA purchased a new position in shares of Pfizer during the 1st quarter worth $215,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America raised their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.41.

Pfizer Stock Up 1.1%

Shares of NYSE:PFE opened at $27.37 on Friday. The business has a 50-day moving average price of $24.67 and a 200 day moving average price of $24.14. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $155.59 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.